^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    KBA1412

    i
    Other names: KBA1412, AT1412
    Company:
    AIM Therap, Kling Bio
    Drug class:
    CD9 inhibitor
    Related drugs:
    3ms
    Study of KBA1412 in Participants With Advanced Solid Malignant Tumors (clinicaltrials.gov)
    P1, N=16, Completed, Kling Biotherapeutics B.V. | Recruiting --> Completed | N=106 --> 16 | Trial completion date: Jan 2025 --> Jul 2024 | Trial primary completion date: Jan 2025 --> Jul 2024
    Trial completion • Enrollment change • Trial completion date • Trial primary completion date • Combination therapy • Metastases
    |
    Keytruda (pembrolizumab) • KBA1412